Merck & Co., Inc. (NYSE:MRK) Stock Rating Lowered by Zacks Research

Merck & Co., Inc. (NYSE:MRK) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Monday, Zacks reports.

Several other research firms have also commented on MRK. Argus boosted their price objective on shares of Merck & Co., Inc. from $145.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday, August 25th. Daiwa Securities Group raised shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price objective on the stock in a research note on Wednesday, August 12th. Royal Bank Of Canada dropped their target price on shares of Merck & Co., Inc. from $150.00 to $145.00 and set a “sector perform” rating for the company in a report on Monday, October 12th. Cantor Fitzgerald lifted their target price on shares of Merck & Co., Inc. from $120.00 to $145.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. Finally, Wells Fargo & Company upped their price target on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the company an “overweight” rating in a report on Friday, September 4th. Seventeen research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and an average target price of $151.92.

Merck & Co., Inc. Stock Up 3.2%

MRK opened at $148.19 on Monday. The business’s fifty day moving average is $146.22 and its two-hundred day moving average is $129.67. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The company has a market cap of $365.62 billion, a price-to-earnings ratio of 118.55, a PEG ratio of 6.64 and a beta of 0.21. Merck & Co., Inc. has a one year low of $82.01 and a one year high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The company had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same quarter in the prior year, the company earned $2.13 earnings per share. Merck & Co., Inc.’s revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts anticipate that Merck & Co., Inc. will post 2.66 EPS for the current fiscal year.

Insider Buying and Selling at Merck & Co., Inc.

In related news, EVP David Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the sale, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. This trade represents a 62.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jennifer Zachary sold 80,315 shares of the business’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the transaction, the executive vice president directly owned 45,509 shares of the company’s stock, valued at $6,073,631.14. The trade was a 63.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is owned by company insiders.

Hedge Funds Weigh In On Merck & Co., Inc.

Institutional investors have recently modified their holdings of the company. BlackRock Inc. grew its stake in shares of Merck & Co., Inc. by 0.5% in the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after purchasing an additional 1,073,507 shares during the last quarter. State Street Corp raised its holdings in shares of Merck & Co., Inc. by 0.9% in the 2nd quarter. State Street Corp now owns 120,413,256 shares of the company’s stock worth $15,573,754,000 after purchasing an additional 1,087,583 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Merck & Co., Inc. by 2.3% in the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock worth $11,083,033,000 after purchasing an additional 1,934,312 shares in the last quarter. Bank of America Corp DE lifted its stake in Merck & Co., Inc. by 10.5% during the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock valued at $3,701,831,000 after purchasing an additional 2,919,780 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Merck & Co., Inc. by 23.8% during the first quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company’s stock valued at $1,858,938,000 after purchasing an additional 2,969,856 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s newer cancer treatments and encouraging Phase 3 melanoma results may help broaden its oncology franchise and reduce reliance on Keytruda. Investors are assessing whether these products can become meaningful growth drivers before Keytruda faces patent-related competition. How Investors Are Reacting To Merck Phase 3 Melanoma Results
• Positive Sentiment: The company’s diversified drug portfolio, research investments and dividend—approximately a 2.4% yield—provide support for investors seeking income while waiting for newer therapies to offset future Keytruda pressure. Merck also previously raised its 2026 sales outlook. Merck’s 2.4% Dividend Yield
• Neutral Sentiment: Merck KGaA agreed to acquire Silence Therapeutics for approximately $1.3 billion in cash, including $20 per American depositary share. The deal could strengthen the German company’s pipeline, but Merck KGaA is a separate company from U.S.-listed Merck & Co. (MRK), so the transaction does not directly affect MRK’s earnings or stock.
• Negative Sentiment: Keytruda’s concentration creates a significant patent-cliff risk. New treatments must scale rapidly enough to replace a large portion of sales and profits when competition arrives, adding uncertainty to Merck’s valuation and long-term growth outlook. Merck Has New Cancer Treatments
• Negative Sentiment: Exchange-traded funds were reported as net sellers of MRK, indicating some short-term institutional or systematic selling pressure despite the company’s underlying growth initiatives. ETFs Are Net Sellers of Merck

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.